Avadel Pharmaceuticals (AVDL) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Avadel Pharmaceuticals is expected to announce its Q2 2025 earnings on Thursday, August 7th, with anticipated earnings of $0.02 per share and revenue of $60.28 million.
• The company reported a revenue increase of 93.2% year-over-year in its last quarterly earnings, exceeding analysts' expectations.
• Research analysts maintain a "buy" rating on Avadel Pharmaceuticals, with an average target price of $18.33 per share.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $60.28 million for the quarter. Avadel Pharmaceuticals has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. Avadel Pharmaceuticals had a negative return on equity of 36.07% and a negative net margin of 13.58%. The business had revenue of $52.51 million for the quarter, compared to analyst estimates of $50.57 million. During the same quarter in the previous year, the firm earned ($0.30) EPS. The company's quarterly revenue was up 93.2% compared to the same quarter last year. On average, analysts expect Avadel Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Avadel Pharmaceuticals Stock Performance

Shares of NASDAQ AVDL traded up $0.57 during trading on Friday, hitting $11.08. 993,391 shares of the company were exchanged, compared to its average volume of 1,336,456. Avadel Pharmaceuticals has a 12-month low of $6.38 and a 12-month high of $17.30. The company has a fifty day moving average price of $9.74 and a 200-day moving average price of $8.74. The firm has a market capitalization of $1.07 billion, a PE ratio of -41.04 and a beta of 1.42.

Wall Street Analyst Weigh In

Several research analysts have recently commented on AVDL shares. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of Avadel Pharmaceuticals in a report on Friday, July 18th. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 target price on shares of Avadel Pharmaceuticals in a research report on Thursday, May 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Avadel Pharmaceuticals has an average rating of "Buy" and an average target price of $18.33.

Institutional Investors Weigh In On Avadel Pharmaceuticals

A hedge fund recently raised its stake in Avadel Pharmaceuticals stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) by 4.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 54,885 shares of the company's stock after acquiring an additional 2,291 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.06% of Avadel Pharmaceuticals worth $430,000 as of its most recent filing with the SEC. 69.19% of the stock is owned by institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.